Oligonucleotide Synthesis Market Size (2025 – 2030)

The Global Oligonucleotide Synthesis Market was valued at USD 3.3 billion in 2024 and is projected to reach a market size of USD 6.5 billion by the end of 2030. Over the forecast period of 2025-2030, the market is projected to grow at a CAGR of 14.51%.   

Oligonucleotide synthesis is the process of creating short DNA or RNA molecules, oligonucleotides, in a set sequence. They may be anything from a few bases to about 200 nucleotides in length. It is done chemically in a controlled laboratory setting, most often with solid phase phosphoramidite chemistry. In this procedure, nucleotides are added one by one to an extending chain, and each addition includes a series of chemical reactions. This technology allows researchers to design custom-made oligonucleotides for multiple uses, such as gene synthesis, polymerase chain reaction (PCR), gene editing tools like CRISPR-Cas9, and molecular diagnostic tests. Progress in oligonucleotide synthesis has worked wonderfully in accelerating research in genomics and molecular biology, which underpins most of the advancements in medical and biological research.

 Key Market Insights:

• Synthetic oligonucleotides are also investigated as solutions for data storage, as DNA is able to carry very large amounts of information in a small space.
• Progress in gene technology is also using oligonucleotide synthesis for food production to increase yields and nutritional quality of crops.
• The market is dominated by high fragmentation and a lot of players making their contribution towards market growth. It is expected to become more pronounced, and with that comes large opportunities for service providers of services. In January 2023, Agilent Technologies Inc. reported the expansion of its therapeutic nucleic acid manufacturing with two oligonucleotide production lines added at its Frederick, Colorado plant. This investment follows the industry's reaction to heightened demand for oligonucleotide-based treatments.

Global Oligonucleotide Synthesis Market Drivers:

The demand for the healthcare and pharmaceutical industries is rising which is driving the market growth.

The demand for therapeutics and personalized medicine globally is on the verge of rising quickly, which in turn has fueled an unprecedented growth in the market for oligonucleotide synthesis. The sequences that are synthesized form a fundamental part in constructing targeted therapies against various genetic diseases and disorders, like cancer. Concomitantly, with the growth, therapeutic oligonucleotides, including antisense oligonucleotides, aptamers, siRNAs, and immunostimulatory oligonucleotides, are changing the paradigm in the treatment of disease through targeted inhibition or gene expression modulation. In addition, the preparation of bespoke oligonucleotides is central to vaccine manufacturing, such as mRNA COVID-19 vaccines, which have been found to be effective and have become standard. With more pharmaceutical entities and scientists finding new uses for oligonucleotides in disease prevention and treatment, oligonucleotide synthesis will increase.

Technological Advancements and Innovation have made a positive impact on market growth.

The continued improvement and advancement of oligonucleotide synthesis technologies are propelling market growth. Furthermore, advancements in the synthesis process, such as high-throughput and automated synthesis systems, have improved the efficiency, precision, and scalability of oligonucleotide manufacturing. Additionally, advancements in synthetic biology and bioinformatics, such as DNA sequencing and gene editing (e.g., CRISPR-Cas9), depend extensively on the capacity to synthesize oligonucleotides precisely. These advancements enable the construction of bespoke sequences with increased diversity and complexity and enable quick prototype testing in synthetic biology, hence enabling more efficient research and development. These ongoing technological developments and advancements are also driving the market.

Global Oligonucleotide Synthesis Market Restraints and Challenges:

The increasing therapeutic use of oligonucleotides has led to stricter quality control measures and compliance requirements from regulatory bodies such as the FDA and EMA.

The expanding therapeutic uses of oligonucleotides have pushed regulatory agencies like the FDA (Food and Drug Administration) and EMA (European Medicines Agency) to tighten quality control processes and enforce compliance. With an increasing presence of oligonucleotide therapies as treatments for genetic diseases, orphan diseases, and cancer, regulatory agencies are enforcing rigorous guidelines to confirm their safety, effectiveness, and consistency of manufacture. Such regulations include thorough clinical trials, stringent documentation, and compliance with Good Manufacturing Practices (GMP), substantially raising the cost and time involved in drug development. Moreover, the dynamic nature of regulatory procedures necessitates frequent revisions to compliance strategies, which poses hurdles to smaller biotech companies and new market entrants to navigate the approval process successfully. Missing these strict conditions may result in holdups, additional scrutiny, or even dismissal of therapeutic prospects, thus affecting market expansion and innovation in oligonucleotide-based therapies.

Global Oligonucleotide Synthesis Market Opportunities:

The worldwide oligonucleotide synthesis market offers strong opportunities fueled by advances in gene therapies, synthetic biology, and personalized medicine. As the incidence of genetic disorders and infectious diseases increases, oligonucleotides find wider applications in therapeutics, diagnostics, and drug discovery. Growth in mRNA-based technologies, which have been catalyzed by the success of COVID-19 vaccines, has further fueled demand. Moreover, advances in automation and high-throughput synthesis techniques are improving the efficiency and scalability of production. New applications like DNA-based data storage, gene editing using CRISPR, and agricultural biotechnology present promising opportunities. Strategic partnerships among biotech companies, pharmaceutical players, and research institutions are promoting market growth, while growing investments in R&D are impelling innovation in next-generation oligonucleotide-based solutions.

OLIGONUCLEOTIDE SYNTHESIS MARKET REPORT COVERAGE:

Global Oligonucleotide Synthesis Market Segmentation:

Oligonucleotide Synthesis Market Segmentation: By Product

• Reagents
• Synthesized Oligonucleotide Products
• Services
• Equipment

The demand for oligonucleotide synthesis products is being fueled by the continuously expanding need from the pharmaceutical and biotech industries for drug discovery and development, particularly for targeted therapeutics and personalized medicine. Coupled with this, the increased genomics and molecular research, prompted by major technological advancements in Next Generation Sequencing (NGS) and CRISPR gene editing, is increasing the need for synthesized oligonucleotides. Also, increasing oligonucleotide diagnostic usage in PCR and microarray genetic and infectious disease tests is driving the market. Increasing epigenetic research opportunities represent another strong driving force for which oligonucleotides are an integral tool in studies on gene expression. In addition, the rising incidence of genetic diseases and the consequent demand for new treatment modalities utilizing oligonucleotides contribute to further accelerating the market development for synthesized oligonucleotide products.

Oligonucleotide Synthesis Market Segmentation: By Application

• Sequencing
• DNA Microarrays
• PCR Primers
• PCR Assays and Panels
• Others

Demand for PCR primers in the oligonucleotide synthesis market is fueled by the global health crisis that has created a huge need for massive viral testing, in which PCR is a main technique. Additionally, the growth of the use of PCR in medical diagnostics, forensics, and research to identify genetic mutations and infectious diseases drives primer demand. In the realm of genomics and molecular biology, PCR is an essential tool for DNA sequencing, cloning, and genetic engineering, and this extensive application further propels the demand for PCR primer synthesis. Besides, advances in PCR technology, including real-time PCR and digital PCR, are also contributing to the demand. Increased financing of research within healthcare and life sciences has also led to increased application of PCR, thereby pushing the demand for PCR primers in the entire industry.

Oligonucleotide Synthesis Market Segmentation: Regional Analysis:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

The North American oligonucleotide synthesis market is driven by the strong pharmaceutical and biotech industry with an emphasis on drug development and discovery. The regional interest in targeted therapies and personalized medicine also drives this demand. North America's advanced healthcare system with enhanced diagnostic capabilities also enhances the demand for oligonucleotides in diagnostic assays. It is also home to many premier educational and research centers performing high-volume genomics and molecular biology work, requiring the synthesis of oligonucleotides. Also, the increased investment from the government and the private sector in the life sciences and healthcare research fields, specifically genomics and personal medicine, accelerates the industrial development of North America. Additionally, the advancements in formulation and delivery systems for oligonucleotide therapeutics in North America indicate that the region is dedicated to breaking new ground in innovation in this arena. These advances not only fuel the expansion of the market but also have the propensity to transform the treatment of numerous diseases, such as genetic illnesses, cancers, and orphan diseases.

COVID-19 Impact Analysis on the Global Oligonucleotide Synthesis Market:

The COVID-19 pandemic significantly affected the world's oligonucleotide synthesis market, both as a threat and an opportunity. First, supply chain disruptions, labor shortages, and logistical issues hindered the production and delivery of oligonucleotides. But the quick development of mRNA vaccines, including those by Pfizer-BioNTech and Moderna, greatly increased the demand for oligonucleotide synthesis. The pandemic brought to the fore the pivotal importance of synthetic oligonucleotides for vaccine, diagnostic, and antiviral development, resulting in the resultant surge in biopharmaceutical R&D spending. Additionally, the crisis accelerated innovation in automation and high-throughput synthesis methods in response to the pressing global demands. Consequently, the market saw long-term growth prospects, with new areas of application in infectious disease research, precision medicine, and next-generation therapeutics beyond COVID-19.

Latest Trends/ Developments:

The international oligonucleotide synthesis market has seen a number of major developments over the past few years, demonstrating the sector's rapid growth and progress. GenScript widened its main manufacturing facility in Zhenjiang, Jiangsu, China, in May 2023 to boost the production of oligonucleotides and peptides, affirming its 20-year track record of delivering high-quality products to researchers globally. Moreover, in February 2022, Kaneka Eurogentec S.A. (Kaneka Corporation) successfully produced a 25 g batch of mRNA for a U.S. customer at its Belgian facility. Eurogentec's GMP mRNA manufacturing service now includes in vitro transcription (IVT), purification, quality control, and batch release at a scaleable level. Such strategic developments reflect the mounting investments and technological advancements in oligonucleotide synthesis and place the market for future growth and innovation.

Key Players:

1. Agilent Technologies Inc.
2. Bio-Synthesis Inc.
3. GenScript
4. Horizon Discovery Ltd
5. Biolegio B.V.
6. Integrated DNA Technologies Inc.
7. LGC Limited
8. Eurofins Genomics
9. Thermo Fisher Scientific Inc.
10. Kaneka Eurogentec S.A.